Although the current World Health Organization (WHO) recommended management package for acute diarrhoea (ORS, zinc and feeding advice) has contributed to significant reductions in diarrhoea associated mortality, over half a million children continue to die annually as a result of acute diarrhoeal episodes. In addition, rates of mortality in young children in the 90 days following an episode of acute diarrhoea appear at least as high as mortality that occurs during the acute episode. The long-term benefits of antibiotic administration may result from direct antimicrobial effects on pathogens or from other incompletely understood mechanisms including improved nutrition, alterations in immune tolerance or improved enteric function. Optimizing antibiotic treatment of acute diarrhoea episodes in very young children with severe disease may offer the opportunity to significantly reduce diarrhoea associated deaths in the 180 days following presentation for acute diarrhoea and may also improve growth. The investigators propose to evaluate the efficacy of an antibiotic (azithromycin) delivered in a specific, targeted fashion to young children (\< 2 years of age) at high risk of diarrhoea associated mortality in a multi-site randomized, double-blind, placebo-controlled trial. The study will evaluate the ability of the intervention to reduce mortality within 180 days of the acute diarrhoeal episode, and improve nutritional status over the first 90 days.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
8,268
Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days
Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 0.25 ml / kg of placebo drug syrup per day, for three days
Icddr,B
Dhaka, Bangladesh
Centre for Public Health Kinetics
New Delhi, India
Kenya Medical Research Institute
Nairobi, Kenya
Malawi-Liverpool-Wellcome Trust Clinical Research Programme
Blantyre, Malawi
Centre pour le Développement des Vaccins (CVD-Mali)
Bamako, Mali
Aga Khan University
Karachi, Pakistan
Muhimbili University of Health and Allied Sciences
Dar es Salaam, Tanzania
Mortality
Proportion of children dying per arm
Time frame: 180 days from enrolment
Linear growth
Mean change in length-for-age Z-score per arm. The Z score will be arrived at from the WHO growth charts based on length in cms and age in months
Time frame: 90 days from enrolment
Hospitalizations upto Day 90
Proportion of children with at least one hospitalization upto Day 90 per arm
Time frame: 90 days
Hospitalization or deaths upto day 90
Proportion of children with at least one hospitalization or death upto day 90 per arm
Time frame: 90 days
Early hospitalization or death (upto day 10)
Proportion of children with death or any hospitalization per arm (upto day 10)
Time frame: 10 days
Change in weight for length Z score
Mean change in weight-for-length Z-score per arm. The Z score will be arrived at from the WHO growth charts based on weight in kg and length in cm for each child
Time frame: 90 days
Change in weight for age Z score
Mean change in weight-for-age Z-score per arm. The Z score will be arrived at from the WHO growth charts based on weight in kg and age in months for each child
Time frame: 90 days
Change in Mid upper arm circumference
Mean change in MUAC (mm) per arm
Time frame: 90 days
Antimicrobial resistance in the community
Proportion of study participants per arm harbouring antibiotic resistant E. coli bacteria in their stools before any intervention
Time frame: Baseline
Antimicrobial resistance among the study participants (sub-group)
Proportion of study participants per arm harbouring antibiotic resistant S. pneumoniae bacteria in the naso-pharynx or E. coli bacteria in their stools
Time frame: At the end of intervention (90 days) and three months later (180 days)
Antimicrobial resistance among close household child contacts (sub-group)
Proportion of siblings or other close household contacts (6-59 months old) per arm harbouring antibiotic resistant S. pneumoniae bacteria in the nasopharynx or E. coli bacteria in their stools
Time frame: At the end of intervention (90 days) and three months later (180 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.